Since 1984, GBC has advanced diagnostics from immunodiagnostics and molecular diagnostics to automated testing and liquid biopsy.
Learn MoreInnovating Diagnostics,
Advancing the Future
Building on four decades of diagnostic expertise, GBC is advancing next-generation precision diagnostics across immunodiagnostics, molecular diagnostics and liquid biopsy.
GBC is building three core platforms: CLIA, automated molecular diagnostics and CellBio™ liquid biopsy, while expanding into antimicrobial peptide and healthcare innovation through GBP.
GBC CL i120 Earns EU IVDR Certification, Marking New Milestone in Global CLIA Expansion
Hsinchu, Taiwan – August 25, 2026 GBC, a precision medicine company (TWSE: 4117), today announced that its GBC CL i120 Fully Automated Chemiluminescence Immunoassay System has recently obtained…
GBC’s Sustainability Journey: From Diagnostic Innovation to Responsible Operations
From environmental management and people development to responsible governance, GBC is integrating sustainability into its operations and long-term development.
Events
Meet GBC at events worldwide and explore our latest innovations in diagnostics.
Join GBC
Unfold Your Future — Join GBC to Innovate Diagnostics and Advance Global Healthcare
Reveal. Better Life.
From precision diagnostics to clinical applications, GBC connects science with healthcare to create meaningful impact for patients and communities worldwide.